



# MONACO GLOBE SPECIALISATION UMBRELLA FUND UNDER MONACO LAW SUB-FUND MONACO SANTÉ

Adjustment of the complete prospectus in accordance with the regulations of the Loi 1.339 as of September 7th, 2007 and of the Ordonnance Souveraine 1.285 of September 10th, 2007, approved as of January 6th, 2009 by the Commission de Contrôle des Activités Financières

The complete prospectus is available to clients at any CMB branch

Type of fund:  
international equities

Reference currency:  
Euro

Recommended investment horizon:  
minimum 3 years

Allotment of results:  
capitalized

Frequency of net asset value calculation:  
daily

Pricing method:  
closing prices

Conditions of subscription/redemption:  
with CMB, valued at the day's close as calculated on the following day, for orders placed until 11.00 am

Inception date:  
September 28<sup>th</sup>, 2001

Fund manager:  
C<sup>ie</sup> Monégasque de Gestion SAM  
13 bd Princesse Charlotte  
Principality of Monaco

Depository bank:  
C<sup>ie</sup> Monégasque de Banque SAM  
23 avenue de la Costa  
Principality of Monaco

Publication of Net Asset Value:  
in the "Journal Officiel de Monaco" and posted in the head office of CMB and its branches.

The Net Asset Value of our funds is published and updated on a regular basis on our web page [www.cmb.mc](http://www.cmb.mc)

## Description

The fund is specialised in the Healthcare sector and invests in equities on a global basis. The fund manager may invest part of the portfolio in money market products or keep a portion of the fund in cash, depending on the market conditions.

## Investment objective

The fund is suitable for clients looking to build an exposure to International stock markets in the Healthcare sector. It is a financial instrument in which the client may invest part of his assets, with a recommended investment horizon of at least 3 years. The objective of the fund is to generate capital gains in the long run. In the case where an investment for a shorter time horizon is considered, the client should be informed about the levels of volatility and risk inherent to stock markets in the short run.

## Management style

The fund is managed actively.

The first step in the creation of the portfolio consists in an investment strategy which is split between an analysis of economic conditions and a detailed analysis of the markets, in order to define investment opportunities on a geographic level in the Healthcare sector. The fund seeks an optimum risk diversification with the objective to generate capital gains in the long term.

The second step consists in the selection of individual stocks, depending on their valuation, on their financial strength and on their long-term growth outlook.

The selection of the stocks held in the portfolio is executed primarily in respect of their valuation ratios. The analysis of the balance sheets, to check the level of debt for example, is completing this approach, so as to assure that investments take place in financially sound companies.

The fund is taking advantage of the cooperation with well known financial intermediaries and institutions to access top information about the identified companies and their businesses.

The stocks held in the portfolio are monitored on a daily basis in order to manage efficiently the volatility of the markets. Technical analysis is used for tactical decisions. As a result, the exposure in selected stocks, benefiting from a positive momentum, may be increased, while it may be reduced for stocks with a perceived risk of short-term depreciation.

## Investment universe

The fund invests in the major markets in developed economies: in the United States, in Canada, in the countries of the Euro Zone, in the UK, in the Scandinavian countries, in Switzerland, in Japan and in Asia ex Japan.

Positions are taken in companies from the Healthcare industry active in biotechnology, pharmaceuticals, healthcare machines and devices production and healthcare services. Given the primary orientation of the investment policy towards value, positions in all market capitalisations companies are not excluded.





**MONACO SANTE**  
Monthly report


Net Asset Value as of June 30th, 2010: 1,383.31 €  
Monthly Performance: -0.9 %

**Performance**

**Historic performance**



**Trailing 12 months performance (basis 100)**



Past performance does not guarantee future performance. 2010 performance data is not audited.

**Market strategy**

In June, there was a continued correction in the equity markets, with the S&P500 losing 5.4%, the Eurostoxx300 down 1.4% and the Topix down 4.4%.

Equity investors remained nervous over the world in the wake of various factors, notably on account of austerity plans and fiscal consolidation measures adopted by most G20 countries. At the same time, confidence in the soundness of western banks remained moderate and uncertainties concerning growth in China and also, disappointing consumer confidence data in the United States did not justify hopes of strong renewed global growth.


The Healthcare sector outperformed the general indices (S&P500 Healthcare -1.9%, Eurostoxx Healthcare +0.4%, Topix Pharma +1.5%). Besides the defensive nature of the sector, which had a positive influence on pharmaceutical stocks in a context characterised by strong investor aversion to risk, some positive news supported the sector's leading stocks. In particular, Astrazeneca and Shionogi won a legal action in the US against the manufacturers of generics in respect of the Crestor drug, which is used to control cholesterol levels and which accounts for 4.5 billion dollars of sales revenue. In addition, Novartis and Mitsubishi Tanabe recorded new positive results in the US concerning one of their new drugs for treating multiple sclerosis.

At the same time as G20 countries implemented austerity measures to reduce their debt levels, weak growth gave investors cause to fear a future deflationary environment. Current attractive stock valuations was not sufficient cause for renewed optimism in equity markets. Nonetheless, the soundness of pharmaceutical companies' balance sheets and recurring cash flow provided a sense of security in a depressed market.

**Main positions**

<b>Pfizer (United States)</b> .....	<b>4.1%</b>	<b>Roche Holding (Switzerland)</b> .....	<b>2.8%</b>
<b>Eli Lilly (United States)</b> .....	<b>3.2%</b>	<b>Sanofi-Aventis (France)</b> .....	<b>2.8%</b>
<b>Abbott Laboratories (United States)</b> .....	<b>2.8%</b>	<b>Bristol Myers Squibb (United States)</b> .....	<b>2.7%</b>

**Market capitalization distribution**



**Geographic distribution**

